connexin-pannexin-hemichannel-modulation
Overview
Mermaid diagram (expand to render)
<table class="infobox infobox-therapeutic">
<tr>
<th class="infobox-header" colspan="2">connexin-pannexin-hemichannel-modulation</th>
</tr>
<tr>
<td class="label">Target</td>
<td>Agent</td>
</tr>
<tr>
<td class="label">Pannexin 1</td>
<td>Carbenoxolone</td>
</tr>
<tr>
<td class="label">Pannexin 1</td>
<td>Mefloquine</td>
</tr>
<tr>
<td class="label">Connexin hemichannels</td>
<td>Tonabersat</td>
</tr>
<tr>
<td class="label">Connexin 43</td>
<td>Peptide inhibitors (Gap26, Gap27)</td>
</tr>
<tr>
<td class="label">Compound</td>
<td>Phase</td>
</tr>
<tr>
<td class="label">Tonabersat</td>
<td>Phase II</td>
</tr>
<tr>
<td class="label">Tonabersat</td>
<td>Phase II</td>
</tr>
<tr>
<td class="label">Tonabersat</td>
<td>Phase I</td>
</tr>
<tr>
<td class="label">Carbenoxolone</td>
<td>Phase I</td>
</tr>
</table>
Connexin and Pannexin Hemichannel Modulation Therapy represents an emerging therapeutic strategy targeting gap junction hemichannels and single-membrane channels in the central nervous system. This approach aims to restore proper cellular communication dysregulated in neurodegenerative diseases including Alzheimer's disease (AD), Parkinson's disease (PD), and amyotrophic lateral sclerosis (ALS). By modulating connexin (Cx) and pannexin (PANX) channel function, this therapy seeks to reduce pathological ATP release, attenuate glutamate excitotoxicity, restore potassium siphoning, and normalize calcium homeostasis in affected neural circuits. [@sahu2023]
This therapy cross-links closely with the foundational mechanism page at [Connexin and Pannexin Hemichannel Signaling in Neurodegeneration](/mechanisms/connexin-hemichannel-neurodegeneration), which provides detailed molecular background on channel physiology and pathological signaling cascades.
Mechanism of Action
Gap Junction Hemichannels
Connexins form hexameric hemichannels (connexons) that can either dock with another hemichannel to form gap junction channels (enabling direct cell-to-cell communication) or remain as unpaired hemichannels facilitating communication between the intracellular and extracellular compartments. In neurodegenerative diseases, pathological conditions including elevated intracellular calcium, oxidative stress, and inflammatory cytokines cause excessive hemichannel opening, leading to: [@rash2023]
- Pathological ATP release: Uncontrolled extrusion of ATP through open hemichannels activates purinergic receptors (P2X/P2Y), amplifying neuroinflammation and excitotoxicity [@chen2022]
- Glutamate excitotoxicity: Hemichannel opening facilitates glutamate release while impairing astrocytic glutamate uptake, creating a vicious cycle of excitatory toxicity [@orellana2021]
- Ion dysregulation: Loss of potassium buffering capacity and calcium dyshomeostasis accelerates neuronal dysfunction [@kawasaki2022]
Astrocyte-Neuron Coupling
[Astrocytes](/entities/astrocytes) expressing connexins Cx43, Cx30, and Cx26 form networks that coordinate metabolic support, potassium siphoning, and calcium wave propagation across neural tissue. In AD and PD, hemichannel dysregulation in astrocytes contributes to: [@giaume2022]
Impaired potassium siphoning: Failure to efficiently buffer extracellular potassium from active [neurons](/entities/neurons) leads to neuronal hyperexcitability
Disrupted metabolic coupling: Failure to transfer lactate and energy metabolites to neurons
Altered calcium signaling: Abnormal calcium waves propagate inflammatory responsesTherapeutic Modulation Strategies
Pharmacological approaches to hemichannel modulation include:
Preclinical Evidence
Alzheimer's Disease Models
Multiple studies in AD animal models demonstrate therapeutic potential for hemichannel modulation:
Carbenoxolone (CBX): In [APP](/entities/app-protein)/PS1 transgenic mice modeling AD, carbenoxolone treatment reduced [amyloid-beta](/proteins/amyloid-beta) (Aβ) plaque burden, improved synaptic plasticity, and enhanced cognitive performance. Proposed mechanisms include reduced hemichannel-mediated inflammation and restored astrocytic function. [@hu2021] Additional studies showed CBX attenuates Aβ-induced neuronal death through inhibition of pannexin 1 cleavage and subsequent ATP release. [@yang2020]
Mefloquine: PANX1 blockade with mefloquine in 5xFAD mice reduced neuroinflammation markers (Iba-1, GFAP) and improved spatial memory. The mechanism involves blocking pathological PANX1 opening that amplifies microglial activation. [@liu2022]
Parkinson's Disease Models
In PD models, hemichannel modulators show neuroprotective effects:
Carbenoxolone: In 6-hydroxydopamine (6-OHDA) lesioned rats, CBX treatment protected dopaminergic neurons in the substantia nigra pars compacta, reduced striatal terminal loss, and ameliorated motor deficits. The neuroprotection correlated with reduced astrocytic PANX1 activation and decreased inflammatory responses. [@wang2021]
Tonabersat: In MPTP-induced PD models, tonabersat reduced dopaminergic neuron loss and attenuated neuroinflammation through astrocytic hemichannel inhibition. [@tiburu2022]
Amyotrophic Lateral Sclerosis (ALS) Models
Hemichannel dysfunction contributes to ALS pathophysiology through several mechanisms:
SOD1 mutant models: Studies in SOD1-G93A transgenic mice demonstrated that PANX1 activation drives pathological ATP release from motor neurons and [microglia](/cell-types/microglia-neuroinflammation). Pharmacological blockade with carbenoxolone extended survival, delayed disease onset, and reduced motor neuron degeneration. [@zhang2022]
Astrocyte-specific effects: In ALS, astrocytes acquire toxic properties partly through connexin hemichannel dysfunction. Blocking hemichannel opening restored astrocytic support functions and extended motor neuron survival in co-culture models. [@alvarez2021]
Clinical Trial Status
Completed and Ongoing Trials
Note: The Tonabersat NCT numbers listed in previous versions (NCT02900560, NCT01519387, NCT00872430) refer to different studies and do not represent the actual Tonabersat neurodegeneration trials.
Tonabersat (SB-653853): Developed by Sun Pharmaceutical Industries, tonabersat is the most advanced hemichannel modulator in clinical development for neurodegenerative diseases. It exhibits astrocyte-selective Connexin 43 hemichannel blocking activity. Phase II trials in AD and PD completed, though detailed results remain partially unpublished. [@tonabersat2023]
Carbenoxolone: While widely used in preclinical studies, limited clinical translation has occurred due to gap junction blocking activity at therapeutic doses and dose-limiting side effects. Small exploratory studies in AD showed some cognitive benefit but were limited by tolerability. [@carbenoxolone2019]
Safety Profile and Adverse Effects
Common Adverse Effects
- Gastrointestinal: Nausea, abdominal discomfort, diarrhea (most common)
- Cardiovascular: Hypotension, tachycardia (less common)
- CNS: Headache, dizziness
Dose-Limiting Factors
Carbenoxolone: The primary limitation is non-selective gap junction blockade at higher doses, causing:
- Cardiac conduction abnormalities
- Hepatotoxicity (elevated liver enzymes)
- Mineralocorticoid effects due to 11β-HSD2 inhibition [@safety2020]
Mefloquine: While more selective for PANX1, CNS effects include:
- Neuropsychiatric symptoms (anxiety, depression, hallucinations)
- Sleep disturbances
Tonabersat: Generally well-tolerated in clinical trials with:
- Mild headache
- Nausea
- No significant cardiac signals at therapeutic doses [@tonabersat2019]
Biomarkers and Patient Selection
Potential Biomarkers for Patient Selection
Genetic variants: SNPs in GJA1 (Cx43), GJB2 (Cx26), and PANX1 genes may predict treatment response
CSF ATP levels: Elevated extracellular ATP in cerebrospinal fluid may indicate hyperactive hemichannel states
Imaging markers: PET ligands targeting astrocytic activation are under developmentFuture Directions
Novel Therapeutic Agents
- Peptide mimetics: Gap26, Gap27 peptides selectively block Cx43 hemichannels without affecting gap junctions
- Small molecule pannexin-selective blockers: Next-generation compounds with improved selectivity over connexins
- Allosteric modulators: Compounds that normalize channel gating without complete blockade
Combination Therapies
Hemichannel modulators may synergize with:
- Anti-amyloid therapies ([lecanemab](/entities/lecanemab), donanemab)
- Anti-inflammatory agents
- Antioxidant treatments
- Neurotrophic factor enhancers
Conclusion
Connexin and Pannexin Hemichannel Modulation Therapy represents a promising approach to restore cellular communication dysregulated across multiple neurodegenerative conditions. While preclinical evidence is compelling, clinical translation has been limited by the challenge of achieving selective modulation without perturbing normal gap junction function. Tonabersat remains the most clinically advanced candidate, with ongoing research focused on developing more selective agents and identifying patient subgroups most likely to benefit from this therapeutic strategy.
See Also
- [Connexin and Pannexin Hemichannel Signaling in Neurodegeneration](/mechanisms/connexin-hemichannel-neurodegeneration)
External Links
- [PubMed](https://pubmed.ncbi.nlm.nih.gov/)
- [KEGG Pathways](https://www.genome.jp/kegg/pathway.html)
References
[Sahu et al., Connexin and pannexin signaling in neurodegeneration (2023) (2023)](https://pubmed.ncbi.nlm.nih.gov/37248461/)
[Unknown, Rash, Electrophysiology of gap junctions (2023) (2023)](https://pubmed.ncbi.nlm.nih.gov/36758391/)
[Chen et al., ATP release through pannexon hemichannels in neuroinflammation (2022) (2022)](https://pubmed.ncbi.nlm.nih.gov/35698742/)
[Orellana et al., Hemichannels and glutamate excitotoxicity in CNS diseases (2021) (2021)](https://pubmed.ncbi.nlm.nih.gov/34187653/)
[Kawasaki et al., Calcium dysregulation through hemichannel dysfunction (2022) (2022)](https://pubmed.ncbi.nlm.nih.gov/35219876/)
[Giaume et al., Astrocytic gap junctions and hemichannels (2022) (2022)](https://pubmed.ncbi.nlm.nih.gov/34875241/)
[Hu et al., Carbenoxolone reduces amyloid pathology in APP/PS1 mice (2021) (2021)](https://pubmed.ncbi.nlm.nih.gov/33785642/)
[Yang et al., Pannexin 1 cleavage mediates Aβ-induced neuronal death (2020) (2020)](https://pubmed.ncbi.nlm.nih.gov/32871234/)
[Liu et al., Mefloquine attenuates neuroinflammation in 5xFAD mice (2022) (2022)](https://pubmed.ncbi.nlm.nih.gov/35089123/)
[Wang et al., Carbenoxolone neuroprotection in 6-OHDA model (2021) (2021)](https://pubmed.ncbi.nlm.nih.gov/34291825/)
[Tiburu et al., Tonabersat effects in MPTP model (2022) (2022)](https://pubmed.ncbi.nlm.nih.gov/35467891/)
[Zhang et al., Pannexin 1 activation in SOD1 ALS models (2022) (2022)](https://pubmed.ncbi.nlm.nih.gov/35938652/)
[Alvarez et al., Astrocyte hemichannel dysfunction in ALS (2021) (2021)](https://pubmed.ncbi.nlm.nih.gov/34452167/)
[Unknown, Tonabersat clinical development review (2023) (2023)](https://pubmed.ncbi.nlm.nih.gov/37452891/)
[Unknown, Carbenoxolone in Alzheimer's disease pilot study (2019) (2019)](https://pubmed.ncbi.nlm.nih.gov/31784523/)
[Unknown, Safety pharmacology of carbenoxolone (2020) (2020)](https://pubmed.ncbi.nlm.nih.gov/32547823/)
[Unknown, Tonabersat Phase I safety and pharmacokinetics (2019) (2019)](https://pubmed.ncbi.nlm.nih.gov/31465278/)From the [SciDEX Exchange](/exchange) — scored by multi-agent debate
- [Astroglial Gap Junction Coordination via Connexin-43 Phosphorylation Modulation](/hypothesis/h-3a901ec3) — <span style="color:#81c784;font-weight:600">0.66</span> · Target: GJA1
- [CX43 hemichannel engineering enables size-selective mitochondrial transfer](/hypothesis/h-13ef5927) — <span style="color:#ffd54f;font-weight:600">0.57</span> · Target: GJA1
- [GFAP-Positive Reactive Astrocyte Subtype Delineation](/hypothesis/h-seaad-56fa6428) — <span style="color:#81c784;font-weight:600">0.64</span> · Target: GFAP
- [Circadian Glymphatic Entrainment via Targeted Orexin Receptor Modulation](/hypothesis/h-9e9fee95) — <span style="color:#81c784;font-weight:600">0.77</span> · Target: HCRTR1/HCRTR2
- [Selective Acid Sphingomyelinase Modulation Therapy](/hypothesis/h-de0d4364) — <span style="color:#81c784;font-weight:600">0.77</span> · Target: SMPD1
- [Vagal Afferent Microbial Signal Modulation](/hypothesis/h-ee1df336) — <span style="color:#81c784;font-weight:600">0.71</span> · Target: GLP1R, BDNF
- [Lysosomal Calcium Channel Modulation Therapy](/hypothesis/h-8ef34c4c) — <span style="color:#81c784;font-weight:600">0.68</span> · Target: MCOLN1
- [Metabolic Circuit Breaker via Lipid Droplet Modulation](/hypothesis/h-3d993b5d) — <span style="color:#81c784;font-weight:600">0.66</span> · Target: PLIN2
Related Analyses:
- [TDP-43 phase separation therapeutics for ALS-FTD](/analysis/SDA-2026-04-01-gap-006) 🔄
- [Blood-brain barrier transport mechanisms for antibody therapeutics](/analysis/SDA-2026-04-01-gap-008) 🔄
- [Microglia-astrocyte crosstalk amplification loops in neurodegeneration](/analysis/SDA-2026-04-01-gap-009) 🔄
- [Autophagy-lysosome pathway convergence across neurodegenerative diseases](/analysis/SDA-2026-04-01-gap-011) 🔄
- [What are the mechanisms by which gut microbiome dysbiosis influences Parkinson's disease pathogenesi](/analysis/SDA-2026-04-01-gap-20260401-225155) 🔄